Minderoo precision brain tumour programme
Research type
Research Study
Full title
Minderoo precision brain tumour programme
IRAS ID
299097
Contact name
Richard Mair
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and The University Of Cambridge
Duration of Study in the UK
8 years, 5 months, 1 days
Research summary
Brain tumours can often be difficult to precisely diagnose and treat. For patients with brain tumours, sequencing of the DNA within tumour cells can help doctors make a more precise diagnosis, help make prognosis clearer, help determine the best treatment options, and help guide patients towards particular clinical trials for which they might be eligible. Many tests looking at tumour DNA examine only small sections of DNA. Whole genome sequencing is where the whole of the DNA present in cancer cells is sequenced and compared with a patient’s normal DNA. We do not yet know how valuable this is for patients with brain tumours, and this study is trying to find this out for a specific type of brain tumour and help with our understanding of changes present in tumour cells that might help us treat current and future patients.
Occasionally, some patients are predisposed to developing brain tumours and other tumours/cancers owing to specific changes in genes that they might have inherited and which might be passed on to other family members. This study also aims to identify potentially heritable changes.
In order to get the most value for future patients with brain tumours, this study also uses other data, scan images and samples that are held in NHS settings, and other approved settings, so that the study team (and collaborators) can put together the fullest picture of participants’ care, and use further laboratory research to find out as much as possible about the disease and how it might be best managed in future. The study also includes extra sample collection (blood tests and urine samples) to help with this.
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
21/EM/0154
Date of REC Opinion
9 Aug 2021
REC opinion
Further Information Favourable Opinion